What can we learn from the FACIT trial: a randomized, double blind, controlled trial by Durga, J. et al.
  
 
What can we learn from the FACIT trial: a randomized,
double blind, controlled trial
Citation for published version (APA):
Durga, J., van Boxtel, M. P. J., Schouten, E. G. W., Kok, F. J., Jolles, J., Katan, M. B., & Verhoef, P.
(2007). What can we learn from the FACIT trial: a randomized, double blind, controlled trial. Journal of
Nutrition Health & Aging, 11(4), 320-324.
Document status and date:
Published: 01/01/2007
Document Version:
Publisher's PDF, also known as Version of record
Please check the document version of this publication:
• A submitted manuscript is the version of the article upon submission and before peer-review. There can
be important differences between the submitted version and the official published version of record.
People interested in the research are advised to contact the author for the final version of the publication,
or visit the DOI to the publisher's website.
• The final author version and the galley proof are versions of the publication after peer review.
• The final published version features the final layout of the paper including the volume, issue and page
numbers.
Link to publication
General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright
owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these
rights.
• Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
• You may not further distribute the material or use it for any profit-making activity or commercial gain
• You may freely distribute the URL identifying the publication in the public portal.
If the publication is distributed under the terms of Article 25fa of the Dutch Copyright Act, indicated by the “Taverne” license above,
please follow below link for the End User Agreement:
www.umlib.nl/taverne-license
Take down policy
If you believe that this document breaches copyright please contact us at:
repository@maastrichtuniversity.nl
providing details and we will investigate your claim.
Download date: 04 Dec. 2019
The Journal of Nutrition, Health & Aging©
Volume 11, Number 4, 2007
320
Introduction
Observational studies show that low folate and elevated
homocysteine concentrations are associated with poor cognitive
performance in the general population. In a double blind
randomized placebo-controlled trial we assessed whether 3-
year folic acid supplementation (0.8 mg) improves cognitive
performance in 818 men and women ages 50-70 years. 
Methods
Assuming that high concentrations of plasma total
homocysteine were a risk factor, we selected participants
expected to benefit from folic acid’s homocysteine-lowering
effect. Participants with concentrations of plasma total
homocysteine <13 µmol/L (73rd percentile of those screened)
were excluded. We excluded participants with possible elevated
homocysteine concentrations due to factors, other than sub-
optimal folate concentrations including: serum vitamin B12
<200 pmol/L (10th percentile of those screened; vitamin B12
concentrations <160 pmol/L indicated vitamin B12 deficiency);
self-reported medical diagnosis of renal or thyroid disease; or
self-reported use of medications that influence folate
metabolism (1). In addition, we excluded participants with self-
reported intestinal disease and participants who reportedly used
B vitamin supplements. At the time of our study folic acid
fortification of foods was prohibited in the Netherlands.
All participants underwent the cognitive performance
assessments after an overnight fast, followed by a glass of juice
and a bread product for breakfast. The tests have been
previously described (2) Trained research assistants
administered the tests during a 40-minute session; they used a
standard text to instruct participants. A third research assistant
periodically observed the testing to ensure that the 2 research
assistants did not deviate from the protocol. All cognitive tests
were conducted in the same room with the same props.
The outcome of the study was the difference between the
folic acid and placebo group in the 3-year change in
performance on the domains: memory, sensorimotor speed,
complex speed, information processing speed and word
fluency. Seventeen participants lost to follow-up were given the
median test score of the total population at the end of the study.
Analyses were conducted on an intention-to-treat basis.
Statistical significance was defined as p<0.05 (two-tailed) and
no adjustments were made for multiple testing.
Results
Serum folate concentrations increased 5-fold and plasma
total homocysteine concentrations decreased by 26% in
participants on folic acid versus placebo. 
Folic acid significantly improved memory (difference in Z-
scores 0.132, 95%CI 0.032; 0.233), information processing
speed (difference in Z-scores 0.087, 95%CI 0.016; 0.158) and
sensorimotor speed (difference in Z-scores 0.064, 95%CI -
0.001; 0.129) (Table 1). Folic acid did not affect complex speed
or word fluency. Folic acid improved performance on several
cognitive functions that tend to decline with age.
In addition to memory and information processing speed,
sensorimotor speed significantly improved (p<0.05) when other
imputation techniques were used (e.g. last value carried
forward, expectation maximization); when 17 participants lost
to follow up were excluded from the analyses; or when 7
participants with initial Mini-Mental State Examination scores
<24 points were excluded from the analyses. Finally, at
baseline, a greater percentage of participants with a low
educational level, an important determinant of cognitive
performance, were randomized into the folic acid group. In
addition, a higher percentage of participants in the folic acid
group had dyslipidemia and self-reported vascular disease. Our
results did not change when we adjusted for these variables.
To illustrate the relevance of our findings we compared the
unstandardized beta of age—adjusted for sex, education and
treatment, calculated using linear regression models with initial
performance as the dependent variable—with the treatment
effect. Three-year folic acid supplementation gives an
individual the performance of someone 4.7 years younger for
memory (95%CI 1.1; 8.3), 1.7 years younger for sensorimotor
speed (95%CI -0.04; 3.4), 2.1 years younger for information
processing speed (95%CI 0.4; 3.7) and 1.5 years younger for
global cognitive function (95%CI 0.1; 2.8).
In contrast to the effects of folic acid on the cognitive tests,
we did not detect an effect on Mini-Mental State Examination
performance (p=0.63). The median score after 3 years was 29
points (28 to 30) and the range was 21 to 30 points in the folic
acid group vs. 16 to 30 points in the placebo group.
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Discussion
The present study may have yielded demonstrable effects of
folic acid on cognitive function because we used sensitive tests
which exist in parallel versions. We also improved the
robustness of the underlying cognitive constructs by clustering
raw test scores over several tests in compound performance
measures. This decreased variation associated with the
individual tests. Finally, clustering of raw tests scores limited
our cognitive performance outcomes to 5 a priori defined
outcomes.
In contrast to other trials we were able to detect an effect of
folic acid on several cognitive functions probably due to a
number of reasons. First, assuming that elevated plasma total
homocysteine concentrations are a causal risk factor for
cognitive decline, we selected a population likely to benefit
from folic acid supplementation. Second, we had a relatively
large study population and supplemented for a relatively long
period. Third, although we did not attempt to measure the
prevalence of dementia at baseline nor its incidence during the
duration of the trial, it is unlikely that our population has many
participants cognitively impaired or demented, as the general
performance on a dementia screening test like the Mini-Mental
State Examination were high, both at the beginning and at the
end of the study. It is plausible that treatment with folic acid or
other B vitamins may be too late in populations with mild
cognitive impairment and dementia. Finally, sensitive tests as
our own, not the commonly used Mini-Mental State
Examination, a dementia screening tool, were needed to detect
the subtle effects of B vitamins on cognitive aging. Importantly,
given the general lack of positive findings from other trials (see
Table 2) and the multiple comparisons made in our trial, our
results need to be confirmed by other investigators to ascertain
whether our statistically significant positive effects of folic acid
on cognitive performance were due to type 1 error.
A strength of our study is the low attrition rate, which
otherwise may bias studies of cognitive change. Participants
with poor cognitive function are likely to withdraw from
studies (13). In our study, the 12 participants in the folic acid
group and 5 participants in the placebo group who did not
return for the end measurements scored lower (0.558 Z-score,
95%CI 0.116; 1.000) on baseline tests of memory only. This is
unlikely to have affected our estimates for several reasons: the
effect of folic acid supplementation on memory did not depend
on baseline performance on the memory tests (data not shown),
the number of participants lost to follow-up was minimal and
the effect estimates based on participants with follow-up data
were similar to the intention-to-treat analyses. A second
strength was the standardized test conditions that reduced
variation due to factors like caffeine and varying breakfasts
(14). 
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Table 1
Mean (standard deviation) change in cognitive performance within groups over 3 years and mean difference (95% confidence
interval) in cognitive change attributed to folic acid supplementation 
Folic acid Placebo Folic acid vs. Placebo
n=405 n=413
Year 0 Year 3 3-year change P value* Year 0 Year 3 3-year change P value* Mean difference P value**
in cognitive in cognitive (95% confidence 
performance performance interval)
Global cognitive function, Z-score
0.006 0.073 0.067 <0.001 -0.048 -0.031 0.017 0.287 0.050 0.033
(0.673) (0.694) (0.338) (0.672) (0.701) (0.332) (0.004; 0.096)
Memory, Z-score
-0.207 0.273 0.480 <0.001 -0.206 0.142 0.348 <0.001 0.132 0.010
(0.959) (0.965) (0.724) (0.883) (0.961) (0.737) (0.032, 0.233)
Sensorimotor speed, Z-score
0.054 0.011 -0.042 0.063 0.019 -0.087 -0.106 <0.001 0.064 0.055
(0.706) (0.753) (0.458) (0.836) (0.819) (0.490) (-0.001, 0.129)
Complex speed, Z-score
0.053 0.026 -0.027 0.405 -0.008 -0.072 -0.064 0.029 0.037 0.40
(0.803) (0.868) (0.651) (0.879) (0.865) (0.593) (-0.049, 0.122)
Information processing speed, Z-score
0.093 0.021 -0.072 0.005 0.024 -0.135 -0.159 <0.001 0.087 0.016
(1.008) (0.967) (0.513) (1.008) (1.008) (0.517) (0.016, 0.158)
Word fluency, Z-score
0.038 0.036 -0.002 0.961 -0.070 -0.002 0.068 0.108 -0.070 0.245
(1.056) (1.029) (0.864) (0.959) (0.953) (0.859) (-0.188, 0.048)
* One sample t-test(0); ** Independent sample t-test.
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Our study had limitations. First, it was conducted in
participants with elevated plasma total homocysteine
concentrations: 3,044 participants out of 4,200 participants
were excluded from the study because of low plasma total
homocysteine concentrations. Thus, the effect of folic acid
supplementation on cognitive function may be greater than
would be expected in populations with lower plasma total
homocysteine concentrations, e.g. in countries like the United
States with mandated fortification of flour with folic acid.
Second, our findings pertain only to vitamin B12-replete
individuals. It has been suggested that folic acid
supplementation exacerbate neurological symptoms in subjects
with vitamin B12 deficiency (15). The possibility of folic acid
mediated exacerbation of neuropathological conditions in
subjects with low levels of vitamin B12 needs to be addressed
by studies that monitor both vitamin B12 status and
neurological function. Our data show that folic acid
supplementation improved sensorimotor speed (difference in Z-
score 0.112 (95%CI 0.001; 0.223) and information processing
speed (difference in Z-score 0.190 (95%CI 0.055; 0.325)) in
230 participants with initial low-normal concentrations of
vitamin B12 (<250 pmol/L), but not in 588 participants with
vitamin B12 concentrations ≥250 pmol/L (difference in Z-scores
0.046 (95%CI -0.033; 0.126) and 0.048 (95%CI -0.036; 0.131),
respectively). As an improvement to our own study,
transcobalamin in addition to vitamin B12, should be measured,
as the former is a better marker of vitamin B12 status. Will folic acid supplementation lead to a decreased
incidence of dementia? While some have argued that cognitive
decline is a beginning of a continuum leading to dementia, (16)
others have argued that the etiology of age-related cognitive
decline differs from that of dementia (17) and that age-related
cognitive decline is not an early state of mild cognitive
impairment or dementia (18). Cognitive tests differ in their
ability to identify individuals who worsen to more advanced
states like mild cognitive impairment or dementia. Of our test
battery, memory is most clinically relevant. Memory can
distinguish between cognitively normal and cognitively
impaired subjects (19). Memory storage (delayed recall), in
particular, can distinguish between subjects with non-
progressive mild cognitive impairment and pre-clinical
Alzheimer’s disease (20). We found that 3-year folic acid
supplementation improves performance on the delayed recall
sub-test of the 15 Word Learning test by 0.47 words (95% CI
0.14; 0.79 words, p=0.005). This improvement is similar to a
performance of an individual 6.9 y younger (95%CI 2.1; 11.8).
Whether folic acid supplementation will prevent dementia is
uncertain. 
Conclusion
We show that 3-year folic acid supplementation improves
performance on tests measuring sensorimotor and information
processing speed and memory in older adults with elevated
total homocysteine concentrations, domains known to decline
with age. Randomized, controlled trials are currently underway
which examine the effect of homocysteine-lowering on
recurrent vascular disease and cognitive function assessed by
the Mini-Mental State Examination or modifications thereof;
these and other homocysteine-lowering trials should include
sensitive measures of cognitive function. In addition, trials
similar to our own need to be repeated in other populations
which give more insight into the clinical relevance of folic acid
supplementation, like in populations with mild cognitive
impairment and dementia.
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